^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    β-catenin inhibitor

    Related drugs:
    2d
    Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers. (PubMed, Cancer Sci)
    Moreover, BB-1701, a novel HER2-ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in vitro and in vivo. These findings indicate that ABC transporter-mediated drug efflux is an important mechanism underlying T-DXd resistance in HER2-positive gastric and lung cancer models. Furthermore, our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effective strategies for overcoming T-DXd resistance in HER2-positive gastric and lung cancers.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Halaven (eribulin mesylate) • BB-1701
    8d
    DPTX3186 in Wnt Pathway Activated Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Dewpoint Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    8d
    NETHER: Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Xijing Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR positive + HER-2 positive
    |
    Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki) • fulvestrant • Halaven (eribulin mesylate)
    11d
    Tegavivint for the Treatment of Relapsed or Refractory Leukemia (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    decitabine • tegavivint (BC2059)
    20d
    DPTX3186 in Wnt Pathway Activated Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Dewpoint Therapeutics
    New P1 trial
    28d
    Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2025 --> Feb 2026
    Trial completion date
    |
    Halaven (eribulin mesylate)
    28d
    Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. (PubMed, Int J Gynaecol Obstet)
    FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC.
    P1 data • Journal • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
    1m
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Emory University | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    gemcitabine • tegavivint (BC2059)
    1m
    Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)
    1m
    E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study. (PubMed, ESMO Open)
    In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    TP53 mutation • KRAS mutation
    |
    E7386
    1m
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
    1m
    OSU-20298: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)